Comparative response to PDT with methyl-aminolevulinate and temoporfin in cutaneous and oral squamous cell carcinoma cells.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 Mar 2024
25 Mar 2024
Historique:
received:
13
12
2023
accepted:
20
03
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
epublish
Résumé
Cutaneous and Head and Neck squamous cell carcinoma (CSCC, HNSCC) are among the most prevalent cancers. Both types of cancer can be treated with photodynamic therapy (PDT) by using the photosensitizer Temoporfin in HNSCC and the prodrug methyl-aminolevulinate (MAL) in CSCC. However, PDT is not always effective. Therefore, it is mandatory to correctly approach the therapy according to the characteristics of the tumour cells. For this reason, we have used cell lines of CSCC (A431 and SCC13) and HNSCC (HN5 and SCC9). The results obtained indicated that the better response to MAL-PDT was related to its localization in the plasma membrane (A431 and HN5 cells). However, with Temoporfin all cell lines showed lysosome localization, even the most sensitive ones (HN5). The expression of mesenchymal markers and migratory capacity was greater in HNSCC lines compared to CSCC, but no correlation with PDT response was observed. The translocation to the nucleus of β-catenin and GSK3β and the activation of NF-κβ is related to the poor response to PDT in the HNSCC lines. Therefore, we propose that intracellular localization of GSK3β could be a good marker of response to PDT in HNSCC. Although the molecular mechanism of response to PDT needs further elucidation, this work shows that the most MAL-resistant line of CSCC is more sensitive to Temoporfin.
Identifiants
pubmed: 38528037
doi: 10.1038/s41598-024-57624-8
pii: 10.1038/s41598-024-57624-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7025Subventions
Organisme : Instituto de Salud Carlos III MINECO and Feder Funds
ID : PI18/00708
Organisme : Instituto de Salud Carlos III MINECO and Feder Funds
ID : PI21/00953
Organisme : Instituto de Salud Carlos III MINECO and Feder Funds
ID : PI21/00953
Organisme : Instituto de Salud Carlos III MINECO and Feder Funds
ID : PI18/00858
Organisme : Instituto de Salud Carlos III MINECO and Feder Funds
ID : PI18/00708
Organisme : Instituto de Salud Carlos III MINECO and Feder Funds
ID : PI18/00708
Organisme : Instituto de Salud Carlos III MINECO and Feder Funds
ID : PI18/00708
Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Dotto, G. P. & Rustgi, A. K. Squamous cell cancers: a unified perspective on biology and genetics. Cancer Cell 29, 622–637 (2016).
pubmed: 27165741
pmcid: 4870309
doi: 10.1016/j.ccell.2016.04.004
Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Prim. 6, 92 (2020).
pubmed: 33243986
doi: 10.1038/s41572-020-00224-3
Alsahafi, E. et al. Clinical update on head and neck cancer: Molecular biology and ongoing challenges. Cell Death Dis. 10, 540 (2019).
pubmed: 31308358
pmcid: 6629629
doi: 10.1038/s41419-019-1769-9
Corchado-Cobos, R., García-Sancha, N., González-Sarmiento, R., Pérez-Losada, J. & Cañueto, J. Cutaneous squamous cell carcinoma: From biology to therapy. Int. J. Mol. Sci. 21, 2956 (2020).
pubmed: 32331425
pmcid: 7216042
doi: 10.3390/ijms21082956
Apalla, Z., Lallas, A., Sotiriou, E., Lazaridou, E. & Ioannides, D. Epidemiological trends in skin cancer. Dermatol. Pract. Concept. 7, 1 (2017).
pubmed: 28515985
pmcid: 5424654
doi: 10.5826/dpc.0702a01
Kallini, J. R., Hamed, N. & Khachemoune, A. Squamous cell carcinoma of the skin: Epidemiology, classification, management, and novel trends. Int. J. Dermatol. 54, 130–140 (2015).
pubmed: 25428226
doi: 10.1111/ijd.12553
Nelson, T. G. & Ashton, R. E. Low incidence of metastasis and recurrence from cutaneous squamous cell carcinoma found in a UK population: Do we need to adjust our thinking on this rare but potentially fatal event?. J. Surg. Oncol. 116, 783–788 (2017).
pubmed: 28703911
doi: 10.1002/jso.24707
Waldman, A. & Schmults, C. Cutaneous squamous cell carcinoma. Hematol. Oncol. Clin. North Am. 33, 1–12 (2019).
pubmed: 30497667
doi: 10.1016/j.hoc.2018.08.001
Sánchez-Danés, A. & Blanpain, C. Deciphering the cells of origin of squamous cell carcinomas. Nat. Rev. Cancer 18, 549–561 (2018).
pubmed: 29849070
pmcid: 7170720
doi: 10.1038/s41568-018-0024-5
Barsouk, A., Aluru, J. S., Rawla, P., Saginala, K. & Barsouk, A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med. Sci. 11, 42 (2023).
Chow, L. Q. M. Head and neck cancer. N. Engl. J. Med. 382, 60–72 (2020).
pubmed: 31893516
doi: 10.1056/NEJMra1715715
Hanahan, D. Hallmarks of cancer: New dimensions. Cancer Discov. 12, 31–46 (2022).
pubmed: 35022204
doi: 10.1158/2159-8290.CD-21-1059
Cramer, J. D., Burtness, B., Le, Q. T. & Ferris, R. L. The changing therapeutic landscape of head and neck cancer. Nat. Rev. Clin. Oncol. 16, 669–683 (2019).
pubmed: 31189965
doi: 10.1038/s41571-019-0227-z
Kim, J. Y. S. et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 78, 560–578 (2018).
pubmed: 29331386
pmcid: 6652228
doi: 10.1016/j.jaad.2017.10.007
Civantos, F. J. et al. A review of photodynamic therapy for neoplasms of the head and neck. Adv. Ther. 35, 324–340 (2018).
pubmed: 29417455
doi: 10.1007/s12325-018-0659-3
Senge, M. O. & Brandt, J. C. Temoporfin (Foscan ®, 5,10,15,20-Tetra( m -hydroxyphenyl)chlorin): A Second-generation Photosensitizer †,‡. Photochem. Photobiol. 87, 1240–1296 (2011).
pubmed: 21848905
doi: 10.1111/j.1751-1097.2011.00986.x
Gondivkar, S. M., Gadbail, A. R., Choudhary, M. G., Vedpathak, P. R. & Likhitkar, M. S. Photodynamic treatment outcomes of potentially-malignant lesions and malignancies of the head and neck region: A systematic review. J. Investig. Clin. Dent. 9, e12270 (2018).
doi: 10.1111/jicd.12270
Juarranz, Á., Jaén, P., Sanz-Rodríguez, F., Cuevas, J. & González, S. Photodynamic therapy of cáncer: Basic principles and applications. Clin. Transl. Oncol. 10, 148–154 (2008).
pubmed: 18321817
doi: 10.1007/s12094-008-0172-2
Agostinis, P. et al. Photodynamic therapy of cancer: An update. CA. Cancer J. Clin. 61, 250–281 (2011).
pubmed: 21617154
pmcid: 3209659
doi: 10.3322/caac.20114
Aniogo, E. C., George, B. P. & Abrahamse, H. Molecular effectors of photodynamic therapy-mediated resistance to cancer cells. Int. J. Mol. Sci. 22, 13182 (2021).
pubmed: 34947979
pmcid: 8704319
doi: 10.3390/ijms222413182
Wang, Y. et al. MAL-PDT inhibits oral precancerous cells and lesions via autophagic cell death. Oral Dis. 25, 758–771 (2019).
pubmed: 30620118
doi: 10.1111/odi.13036
Lucena, S. R. et al. Characterisation of resistance mechanisms developed by basal cell carcinoma cells in response to repeated cycles of Photodynamic Therapy. Sci. Rep. 9, 4835 (2019).
pubmed: 30886381
pmcid: 6423284
doi: 10.1038/s41598-019-41313-y
Berlanda, J., Kiesslich, T., Engelhardt, V., Krammer, B. & Plaetzer, K. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. J. Photochem. Photobiol. B Biol. 100, 173–180 (2010).
doi: 10.1016/j.jphotobiol.2010.06.004
Cerro, P. A. et al. Tumor microenvironment in non-melanoma skin cancer resistance to photodynamic therapy. Front. Oncol. 12, 970279 (2022).
pubmed: 36338755
pmcid: 9634550
doi: 10.3389/fonc.2022.970279
Casas, A., Di Venosa, G., Hasan, T. & Batlle, A. Mechanisms of resistance to photodynamic therapy. Curr. Med. Chem. 18, 2486–2515 (2011).
pubmed: 21568910
pmcid: 3780570
doi: 10.2174/092986711795843272
Gallego-Rentero, M. et al. TGFβ1 secreted by cancer-associated fibroblasts as an inductor of resistance to photodynamic therapy in squamous cell carcinoma cells. Cancers 13, 5613 (2021).
pubmed: 34830768
pmcid: 8616019
doi: 10.3390/cancers13225613
Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69–84 (2019).
pubmed: 30459476
doi: 10.1038/s41580-018-0080-4
Pastushenko, I. & Blanpain, C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 29, 212–226 (2019).
pubmed: 30594349
doi: 10.1016/j.tcb.2018.12.001
Babaei, G., Aziz, S.G.-G. & Jaghi, N. Z. Z. EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomed. Pharmacother. 133, 110909 (2021).
pubmed: 33227701
doi: 10.1016/j.biopha.2020.110909
Lüönd, F. et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev. Cell 56, 3203-3221.e11 (2021).
pubmed: 34847378
doi: 10.1016/j.devcel.2021.11.006
Bai, R. et al. Mechanisms of cancer resistance to immunotherapy. Front. Oncol. 10, 1290 (2020).
pubmed: 32850400
pmcid: 7425302
doi: 10.3389/fonc.2020.01290
Lu, W. & Kang, Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev. Cell 49, 361–374 (2019).
pubmed: 31063755
pmcid: 6506183
doi: 10.1016/j.devcel.2019.04.010
Zhong, Z. & Virshup, D. M. Wnt signaling and drug resistance in cancer. Mol. Pharmacol. 97, 72–89 (2020).
pubmed: 31787618
doi: 10.1124/mol.119.117978
Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B. & Riechelmann, H. Epithelial to mesenchymal transition: A mechanism that fuels cancer radio/chemoresistance. Cells 9, 428 (2020).
pubmed: 32059478
pmcid: 7072371
doi: 10.3390/cells9020428
Nagini, S., Sophia, J. & Mishra, R. Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer. Semin. Cancer Biol. 56, 25–36 (2019).
pubmed: 29309927
doi: 10.1016/j.semcancer.2017.12.010
Alves, M. et al. Glycogen synthase kinase-3 beta expression correlates with worse overall survival in non-small cell lung cancer: A clinicopathological series. Front. Oncol. 11, 621050 (2021).
pubmed: 33767989
pmcid: 7985549
doi: 10.3389/fonc.2021.621050
Walz, A. et al. Molecular pathways: Revisiting glycogen synthase kinase-3β as a target for the treatment of cancer. Clin. Cancer Res. 23, 1891–1897 (2017).
pubmed: 28053024
pmcid: 5392367
doi: 10.1158/1078-0432.CCR-15-2240
Dolcet, X., Llobet, D., Pallares, J. & Matias-Guiu, X. NF-kB in development and progression of human cancer. Virchows Arch. 446, 475–482 (2005).
pubmed: 15856292
doi: 10.1007/s00428-005-1264-9
Xia, L. et al. Role of the NF κ B-signaling pathway in cancer. Onco Targets Ther https://doi.org/10.2147/OTT.S161109 (2018).
doi: 10.2147/OTT.S161109
pubmed: 30573969
pmcid: 6292402
Taniguchi, K. & Karin, M. NF-κB, inflammation, immunity and cancer: Coming of age. Nat. Rev. Immunol. 18, 309–324 (2018).
pubmed: 29379212
doi: 10.1038/nri.2017.142
Esparza-lópez, J. et al. Paclitaxel resistance is mediated by NF-κB on mesenchymal primary breast cancer cells. Oncol. Lett. 23, 50 (2021).
pubmed: 34992683
pmcid: 8721864
doi: 10.3892/ol.2021.13168
Nicolás-Morala, J. et al. In vitro 5-Fluorouracil resistance produces enhanced photodynamic therapy damage in SCC and tumor resistance in BCC. J. Photochem. Photobiol. B Biol. 233, 112483 (2022).
doi: 10.1016/j.jphotobiol.2022.112483
Maytin, E. V. et al. 5-Fluorouracil enhances protoporphyrin IX accumulation and lesion clearance during photodynamic therapy of actinic keratoses: A mechanism-based clinical trial. Clin. Cancer Res. 24, 3026–3035 (2018).
pubmed: 29593028
doi: 10.1158/1078-0432.CCR-17-2020
Adhikary, G. et al. Identification of a population of epidermal squamous cell carcinoma cells with enhanced potential for tumor formation. PLoS One 8, e84324 (2013).
pubmed: 24376802
pmcid: 3869846
doi: 10.1371/journal.pone.0084324
Wiehe, A. & Senge, M. O. The photosensitizer temoporfin (<scp> m THPC </scp> ): Chemical, pre-clinical and clinical developments in the last decade
pubmed: 36161310
doi: 10.1111/php.13730
Ribatti, D., Tamma, R. & Annese, T. Epithelial-mesenchymal transition in cancer: A historical overview. Transl. Oncol. 13, 100773 (2020).
pubmed: 32334405
pmcid: 7182759
doi: 10.1016/j.tranon.2020.100773
Milla, L. N. et al. Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy. J. Cell. Biochem. 112, 2266–2278 (2011).
pubmed: 21503960
doi: 10.1002/jcb.23145
Gilaberte, Y. et al. Cellular intrinsic factors involved in the resistance of squamous cell carcinoma to photodynamic therapy. J. Invest. Dermatol. 134, 2428–2437 (2014).
pubmed: 24717244
doi: 10.1038/jid.2014.178
Semelakova, M. et al. Vimentin and non-muscle myosin IIA are members of the neural precursor cell expressed developmentally down-regulated 9 (NEDD9) interactome in head and neck squamous cell carcinoma cells. Transl. Oncol. 12, 49–61 (2019).
pubmed: 30267961
doi: 10.1016/j.tranon.2018.09.006
Gooding, A. J. & Schiemann, W. P. Epithelial-mesenchymal transition programs and cancer stem cell phenotypes: Mediators of breast cancer therapy resistance. Mol. Cancer Res. 18, 1257–1270 (2020).
pubmed: 32503922
pmcid: 7483945
doi: 10.1158/1541-7786.MCR-20-0067
Cao, Z.-Q., Wang, Z. & Leng, P. Aberrant N-cadherin expression in cancer. Biomed. Pharmacother. 118, 109320 (2019).
pubmed: 31545265
doi: 10.1016/j.biopha.2019.109320
Huo, Y. et al. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells. Oncotarget 7, 45876–45888 (2016).
pubmed: 27322682
pmcid: 5216767
doi: 10.18632/oncotarget.9970
Anand, S. et al. Fluorouracil enhances photodynamic therapy of squamous cell carcinoma via a p53-independent mechanism that increases protoporphyrin IX levels and tumor cell death. Mol. Cancer Ther. 16, 1092–1101 (2017).
pubmed: 28336806
pmcid: 5497500
doi: 10.1158/1535-7163.MCT-16-0608
Vijay, G. V. et al. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. Breast Cancer Res. 21, 37 (2019).
pubmed: 30845991
pmcid: 6407242
doi: 10.1186/s13058-019-1125-0
Caspi, M., Zilberberg, A., Eldar-Finkelman, H. & Rosin-Arbesfeld, R. Nuclear GSK-3β inhibits the canonical Wnt signalling pathway in a β-catenin phosphorylation-independent manner. Oncogene 27, 3546–3555 (2008).
pubmed: 18223684
doi: 10.1038/sj.onc.1211026
Bautista, S. J. et al. mTOR complex 1 controls the nuclear localization and function of glycogen synthase kinase 3β. J. Biol. Chem. 293, 14723–14739 (2018).
pubmed: 30061153
pmcid: 6153275
doi: 10.1074/jbc.RA118.002800
Lingappan, K. NF-κB in oxidative stress. Curr. Opin. Toxicol. 7, 81–86 (2018).
pubmed: 29862377
doi: 10.1016/j.cotox.2017.11.002
Zhang, P. et al. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int. J. Mol. Med. 33, 151–159 (2014).
pubmed: 24173500
doi: 10.3892/ijmm.2013.1538
Gaullier, J. et al. Subcellular localization of and photosensitization by protoporphyrin IX in human keratinocytes and fibroblasts cultivated with 5-aminolevulinic acid. Photochem. Photobiol. 62, 114–122 (1995).
pubmed: 7638255
doi: 10.1111/j.1751-1097.1995.tb05247.x
Sułkowski, L., Pawełczak, B., Chudzik, M. & Maciążek-Jurczyk, M. Characteristics of the protoporphyrin IX binding sites on human serum albumin using molecular docking. Molecules 21, 1519 (2016).
pubmed: 27869697
pmcid: 6273174
doi: 10.3390/molecules21111519
Castano, A. P., Demidova, T. N. & Hamblin, M. R. Mechanisms in photodynamic therapy: Part one—photosensitizers, photochemistry and cellular localization. Photodiagn. Photodyn. Ther. 1, 279–293 (2004).
doi: 10.1016/S1572-1000(05)00007-4
Mossakowska, B. J. et al. Mechanisms of resistance to photodynamic therapy (PDT) in vulvar cancer. Int. J. Mol. Sci. 23, 4117 (2022).
pubmed: 35456936
pmcid: 9028356
doi: 10.3390/ijms23084117
Girotti, A. W. Photosensitized oxidation of membrane lipids: Reaction pathways, cytotoxic effects, and cytoprotective mechanisms. J. Photochem. Photobiol. B Biol. 63, 103–113 (2001).
doi: 10.1016/S1011-1344(01)00207-X
León, D. et al. Epigallocatechin gallate enhances MAL-PDT cytotoxic effect on PDT-resistant skin cancer squamous cells. Int. J. Mol. Sci. 21, 3327 (2020).
pubmed: 32397263
pmcid: 7247423
doi: 10.3390/ijms21093327
Bourré, L. et al. Indirect detection of photosensitizer ex vivo. J. Photochem. Photobiol. B Biol. 67, 23–31 (2002).
doi: 10.1016/S1011-1344(02)00279-8
George, S. & Abrahamse, H. Redox potential of antioxidants in cancer progression and prevention. Antioxidants 9, 1156 (2020).
pubmed: 33233630
pmcid: 7699713
doi: 10.3390/antiox9111156
Giard, D. J. et al. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors2. JNCI J. Natl. Cancer Inst. 51, 1417–1423 (1973).
pubmed: 4357758
doi: 10.1093/jnci/51.5.1417
Rheinwald, J. G. & Beckett, M. A. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res. 41, 1657–1663 (1981).
pubmed: 7214336
Easty, D. M., Easty, G. C., Carter, R. L., Monaghan, P. & Ten Butler, L. J. human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br. J. Cancer 43, 772–785 (1981).
pubmed: 7195729
pmcid: 2010719
doi: 10.1038/bjc.1981.115